Charlestown, MA – According to filings with the U.S. Securities and Exchange Commission, SeLux Diagnostics is raising $57,613,735.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Steve Lufkin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SeLux Diagnostics
Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the worlds deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms.

To learn more about SeLux Diagnostics, visit http://seluxdx.com/

Contact:
Steve Lufkin, Chief Executive Officer
617-945-9383
slufkin@seluxdx.com
https://www.linkedin.com/in/stevelufkin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved